Abstracts tagged "dexamethasone"

Abstract Number: 2200 • 2019 ACR/ARP Annual Meeting
Magnetic Resonance Imaging of Knee Joint Protection Following an Intra-Articular Injection of Lipid-Based Dexamethasone Sodium Phosphate Sustained Release Formulation on Subjects with Knee Osteoarthritis
Sheue-Fang Shih¹, Carl Brown ¹, Tien-Tzu Tai ¹ and Wing Chuang ¹, ¹Taiwan Liposome Company, Ltd., Taipei, Taiwan (Republic of China)
Background/Purpose: The most commonly used intra-articular (IA) corticosteroid for osteoarthritis (OA) is triamcinolone acetonide (TA), but its potential chondrotoxicity restricts injection frequency to 3-4 injections…
Abstract Number: 145 • 2018 ACR/ARHP Annual Meeting
1,25(OH)2D3 and Dexamethasone Additively Suppress Synovial Fibroblast Activation By CCR6+ T-Helper Memory Cells and Enhance the Effect of Tnfα Blockade
W Dankers¹, C González-Leal¹, N Davelaar², P Asmawidjaja³, A Otten-Mus², JMW Hazes⁴, E Colin⁵ and Erik Lubberts⁶, ¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Erasmus Medical Centre, Rotterdam, Netherlands, ⁵ZGT Almelo, Deventer, Netherlands, ⁶Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands
Background/Purpose: Despite improvement in treatment of rheumatoid arthritis (RA) over the past decades, insufficient treatment response and treatment resistance in many patients demonstrate the need…
Abstract Number: 2789 • 2016 ACR/ARHP Annual Meeting
Novel Glucocorticoid Prodrug Effectively Attenuates Late Stage Lupus Nephritis with Improved Safety Profile
Xiaobei Wang¹, Zhenshan Jia², Yangsheng Yu³, Kaihong Su³, James R. O'Dell⁴ and Dong Wang⁵, ¹Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE). Glucocorticoids (GCs) are recommended by ACR as one of the first line…
Abstract Number: 2362 • 2014 ACR/ARHP Annual Meeting
Enhanced Efficacy of Dexamethose with Synovial Fibroblast Targeted Micelles in a Collagen-Induced Arthritis Mouse Model
Rebecca A. Bader, David R. Wilson, Arundhati Ramani and Patricia R. Wardwell, Biomedical & Chemical Engineering, Syracuse University, Syracuse, NY
Background/Purpose: A number of conventional, disease modifying anti-rheumatic drugs (DMARDs) are associated with severe side effects due to non-specific targeting and impaired immune function. To…
Abstract Number: 2317 • 2013 ACR/ARHP Annual Meeting
Impact of PVA Coated Nanoparticles On Cellular Viability and Functionality of Immune Cells Obtained From Healthy Donors and Patients With Rheumatoid Arthritis Or Osteoarthritis
Cindy Strehl¹, Timo Gaber¹, Manuela Jakstadt¹, Martin Hahne¹, Saskia Schellmann¹, Barbara Szostak¹, Géraldine Coullerez², Heinrich Hofmann², Gerd Burmester³ and Frank Buttgereit⁴, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Institute of Materials Powder Technology Laboratory, École polytechnique fédérale de Lausanne, Lausanne, Switzerland, ³Rheumatology and Clinical Immunology, Campus Mitte, Charite University Hospital, Berlin, Germany, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Nanotechnology has developed into a key technology of the 21st century. Over the recent years, the number of nanotechnical products has received an enormous…
Abstract Number: 1275 • 2013 ACR/ARHP Annual Meeting
Prenatal Exposure To Fluorinated Steroids Does Not Affect Long Term Morbidity In Cardiac Neonatal Lupus
Amit Saxena¹, Peter M. Izmirly², Sara Sahl², Deborah Friedman³ and Jill P. Buyon², ¹Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Division of Pediatric Cardiology, New York Medical College, Valhalla, NY
Background/Purpose: Cardiac Neonatal Lupus (NL), characterized by inflammation and fibrosis of the conduction system, endocardium, and myocardium in anti-Ro exposed fetuses, results in significant morbidity…
Abstract Number: 1253 • 2013 ACR/ARHP Annual Meeting
Studies On The Relationship Between Intraplantar Carrageenan-Induced Bradykin B1 Receptor Messenger Ribonucleic Acid Expression and Oedema and Hyperalgesia In Rats: Effects Of Dexamethasone and a B1 Receptor Antagonist, BI-113823
Guy Kennett¹, Jessica Arlott¹, Phil Butler², Mike Comer¹, Andrew Clarkson², Alex Coulthard¹, Sean Lightowler¹, Rachel Upcott-Gill², Rebecca Upton¹, Louise Wray², Philipp Wabnitz³, Sven Kühnert³ and Simon Cruwys³, ¹Saretius Ltd, Reading, United Kingdom, ²Cyprotex Ltd, Macclesfield, United Kingdom, ³Grunenthal GmbH, Aachen, Germany
Background/Purpose: Kinins are a group of peptides formed in plasma and tissues in response to infection, tissue trauma or inflammation (inflamm) whose actions are mediated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].